)

Verve Therapeutics (VERV) investor relations material
Verve Therapeutics Goldman Sachs 46th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Key data and clinical progress
HEART-2 trial of VRRB102 showed up to 60% LDL reduction at highest dose, with strong safety and tolerability across 14 patients.
Durability data from earlier product (VRRB101) demonstrated sustained 60% LDL lowering two years post-infusion, supporting the one-time therapy vision.
VRRB102 uses a new lipid nanoparticle delivery system with GalNAc ligand, improving safety and targeting compared to VRRB101.
Dose escalation continues to identify the optimal fixed dose, with a transition to fixed dosing planned for phase two later this year.
Full dose escalation and durability data will be presented in the second half of the year at a major medical meeting.
Differentiation, safety, and regulatory outlook
VRRB102's delivery system and targeting reduce lab abnormalities seen with earlier versions and competitors.
No read-through expected from recent Intellia liver safety events due to different timing and mechanisms of ALT elevation.
Long-term safety is supported by minimal off-target edits and planned 15-year follow-up for all dosed patients.
Regulatory agencies are increasingly supportive of gene editing, with recent high-profile endorsements and openness to root-cause therapies.
Two-year durability is seen as a strong indicator for long-term efficacy and safety, with payers and agencies likely to credit five years or more if early data remain flat.
Market, patient, and partnership insights
Surveys show strong openness among patients and cardiologists for one-time gene editing, especially in younger and genetically predisposed groups.
Manufacturing costs are expected to be low, enabling flexible pricing and broad market access, distinct from rare disease gene therapies.
Oral PCSK9 options add to chronic care but are not expected to diminish demand for one-time therapies due to persistent unmet need.
Eli Lilly has an opt-in decision for VRRB102 in the second half of the year, potentially sharing US profits and development costs.
Verve's pipeline targets three main cholesterol carriers (PCSK9, ANGPTL3, Lp(a)), with ANGPTL3 in clinic and Lp(a) partnered with Lilly; all leverage the same delivery platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage